We rank companies based on fund manager, research analyst and news sentiment

Akari Therapeutics plc ADR (0.01 USD)


About: Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).

Employees: 12

Funds holding %
of 6,474 funds
Analysts bullish %
News positive %

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

13% more funds holding

Funds holding: 8 [Q3] → 9 (+1) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]

0.0% less ownership

Funds ownership: 0.0% [Q3] → 0.0% (-0.0%) [Q4]

25% less capital invested

Capital invested by funds: $1.19M [Q3] → $892K (-$298K) [Q4]

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

Research analyst outlook

We haven’t received any recent analyst ratings for AKTX.

Financial journalist opinion